drugset / Trial / NCT07483489
A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC/UCC).
Phase 2
Not yet recruiting
180 enrolled
Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC/UCC).
Timeline
- Start
- 2026-05-01
- Primary completion
- 2028-08-30
- Completion
- 2028-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HW091077 | Unknown | — | Oral |